ARCHIVES

Benefit Seen In Novel Drug That Treats Gleevec Resistance

This article is from The Cancer Letter archive.

Vol. 28 No. 4 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

DCCP Board Approves Concepts Of $2.6 Million In New Competing Projects, $1.2 Million In Recompetitions

September 25, 1981

First Phase 0 Oncology Trial Demonstrates Effectiveness Of New Drug On Its Target

April 24, 2009

Trading In Stock Of U.S. Bioscience Halted, Newsletter Report Cited

October 9, 1992

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

December 5, 2014

Funding opportunities listed.

February 13, 2004

Bush Signs Bill To Increase Blood Cancer Research.

May 17, 2002